(trans)-Isomer 3,4- Dichloro- N- methyl- N- (2- (1- pyrrolidinyl)- cyclohexyl)- benzeneacetamide

147  relevant articles (7 outcomes, 11 trials/studies) found for this Bio-Agent

3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)cyclohexyl)-benzeneacetamide Mesylate, (trans)-(+)-Isomer; 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)cyclohexyl)-benzeneacetamide Mesylate, (trans)-(+-)-Isomer; 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)cyclohexyl)-benzeneacetamide Monohydrochloride, (trans)-(+-)-Isomer,; 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)cyclohexyl)-benzeneacetamide Monomethanesulfonate, (trans)-(+)-Isomer; 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)cyclohexyl)-benzeneacetamide Monomethanesulfonate, (trans)-(+-)-Isomer; 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)cyclohexyl)-benzeneacetamide Monomethanesulfonate, (trans)-Isomer; 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)cyclohexyl)-benzeneacetamide, (1R-cis)-Isomer; 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)cyclohexyl)-benzeneacetamide, (1S-cis)-Isomer; 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)cyclohexyl)-benzeneacetamide, (trans)-(+-)-Isomer; 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)cyclohexyl)-benzeneacetamide, (trans)-(-)-Isomer; U-50,488H; U-50488; U-50488H; U50488H; trans-3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide; trans-3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide Hydrochloride; U 50,488H; U 50488; U 50488H; U50,488H; U50488; Benzeneacetamide, 3,4-dichloro-N-methyl-N-(2-(1-pyrrolidinyl)cyclohexyl)-, (trans)-Isomer

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Ma, Sai: 2 articles (09/2007 - 04/2006)
2.	Ma, Xin-Liang: 2 articles (09/2007 - 04/2006)
3.	Bi, Hui: 2 articles (09/2007 - 04/2006)
4.	Pei, Jian-Ming: 2 articles (09/2007 - 04/2006)
5.	Guo, Hai-Tao: 2 articles (09/2007 - 04/2006)
6.	Sun, Xin: 2 articles (09/2007 - 04/2006)
7.	Wang, Yue-Min: 2 articles (09/2007 - 04/2006)
8.	Spetea, M: 2 articles (03/2006 - 01/2001)
9.	Bileviciute-Ljungar, I: 2 articles (03/2006 - 01/2001)
10.	Cheng, Liang: 1 article (09/2007)

Related Diseases

1.	Brain Ischemia (Cerebral Ischemia) 03/01/1993 - "There was no effect on rCBF before MCA occlusion, and the decreased flow after occlusion was enhanced with a significant fall in systemic blood pressure at a dosage of 30 mg/kg. These results indicate that U-50488H has therapeutic potential in cerebral ischemia by mechanisms other than improvement in CBF." 08/01/1994 - "U50488 reduces the severity of tissue damage in a rabbit model of focal cerebral ischemia." 02/14/1991 - "The effect of U-50,488H, a selective kappa-receptor agonist, on memory functions in an animal model of cerebral ischemia was investigated by use of a three-panel runway task" 02/14/1991 - "Effect of the kappa-receptor agonist, U-50,488H, on cerebral ischemia-induced impairment of working memory assessed in rats by a three-panel runway task." Order ALL the reference details at left...
2.	Pain (Aches) 06/28/2004 - "No difference in pain-related behaviour was found between different peripheral (contralateral, ipsilateral and bilateral) treatments with 0.3 mg U-50,488H" 11/13/1990 - "doses of 5, 10 and 35 nmol of U-50,488H produced a gradual reduction of pain scores which was statistically significant at all observation periods" 01/30/1989 - "Since the dorsal raphe nucleus and the region of the central gray pons have been implicated in both analgesia and pain processes a supraspinal site of antinociceptive action of U-50,488H, in addition to a spinal site of action, must be considered." 03/01/2006 - "RESULTS: Contralateral treatment with 0.3 mg U-50,488H into the left hindpaw twice per week reduced the hindpaw oedema, ankle joint inflammation, pain behaviour to mechanical stimuli and severity score of inflammation in the hindpaws of both sides as well as the systemic spread of inflammation to other areas, e.g" 05/12/1994 - "Role of vagal afferents in the antinociception produced by morphine and U-50,488H in the colonic pain reflex in rats." Order ALL the reference details at left...
3.	Ischemia 03/01/2006 - "RESULT: Left ventricular end-diastolic pressure (LVEDP), left ventricular developed pressure (LVDP) and maximal velocity of contraction and relaxation (+/-dP/dtmax) were improved when U50488H was administered 1 or 24 h before ischemia (P<0.05)" 07/01/2008 - "The anti-arrhythmic effects of U50,488H, a selective kappa-OR agonist, in an I/R model of 15-min ischemia were studied followed by 15 min of reperfusion" 02/27/2008 - "The injection of 30 mg/kg U50,488H led to a 65% increase in CA1 neuron survival 35 days post-ischemia" 09/01/2007 - "Rat heart I/R injury was induced by occluding the left anterior descending coronary artery for 45 min and restoring perfusion for 120 min. U50,488H or vehicle was intravenously injected before ischemia" 09/01/2007 - "Cardioprotective and antiarrhythmic effect of U50,488H in ischemia/reperfusion rat heart." Order ALL the reference details at left...
4.	Spinal Cord Injuries (Spinal Cord Injury) 10/29/1993 - "In this study we examined the effects of U-50488H on post-traumatic vascular injury based on the measurement of vascular permeability, edema and neutrophil infiltration in a rat spinal cord injury model" 10/29/1993 - "U-50488H, a selective opioid kappa receptor agonist has been shown to be a neuroprotective agent in animal models of spinal cord injury" 10/29/1993 - "Effect of U-50488h, a selective opioid kappa receptor agonist, on vascular injury after spinal cord trauma." 05/01/1989 - "One hour before a contusive spinal cord injury either compound MK-801 or compound U-50488H was injected intraperitoneally, and a 14-day-delivery osmotic minipump containing the same drug was placed subcutaneously at the time of surgery" 05/01/1989 - "Neuroprotective effect of MK-801 and U-50488H after contusive spinal cord injury." Order ALL the reference details at left...
5.	Ataxia (Dyssynergia) 02/16/1993 - "I.v. administration of U-50,488H after i.v. saline pretreatment produced occasional high-voltage EEG slow-wave bursts that were associated with relatively small increases in spectral power in the 2.5-7.5 Hz band as a spectral peak and with behavioral incidents of sedation, ataxia, ptosis, straub tail, hunching of the back, and backing-up" 02/16/1993 - "After pretreatment with the sigma antagonists rimcazole and DuPont Merck S-7389-4, U-50,488H administration produced significantly larger increases in absolute EEG spectral power, both over the 1-50 Hz range and in the 2.5-5.0 and 5.0-7.5 Hz bands, than after saline pretreatment; rimcazole pretreatment eliminated U-50,488H-induced incidents of ataxia, ptosis, hunching of the back and backing-up" 02/01/2004 - "We determined whether U-50488 (trans-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidinyl)-cyclohexyl]-benzeneacetamide), a kappa opioid receptor agonist, could decrease detrusor-sphincter dyssynergia (DSD) and, thus, improve voiding efficiency in conscious, spinal cord injured (SCI) rats" 04/01/1998 - "A dose-related accentuation of ethanol-induced motor incoordination was observed after direct cerebellar microinfusion of three kappa-opioid receptor agonists: U-50488, U-62066, and bremazocine" Order ALL the reference details at left...

Related Drugs and Biologics

1.	kappa Opioid Receptors (kappa Opioid Receptor)
2.	Morphine (MS Contin)
3.	Dynorphins (Dynorphin)
4.	Trimebutine
5.	Thyrotropin-Releasing Hormone (Prolactin Releasing Hormone)
6.	azetirelin
7.	nalmefene (Revex)
8.	rimcazole
9.	Naloxone (Narcan)
10.	D-Penicillamine (2,5)- Enkephalin

Related Therapies and Procedures

1.	Analgesia
2.	Ligation
3.	Anesthesia